Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Hospital Saint Louis, Paris, France

Survival: 31.2 months
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Herceptin
Country: France
City/State/Province: Paris
Hospital: Hospital Saint Louis
Journal: Link
Date: 7/2005

Patients: This Phase II study involved 186 women with metastatic breast cancer. Ninety-two women (median age 53) were randomly assigned into Group A, and ninety-four (median age 55) were placed into Group B. The median number of metastatic sites was two and included lung, liver, bone, and soft tissue.

Treatment: Patients in Group A received two agents: trastuzumab (Herceptin) a monoclonal antibody and docetaxel (chemotherapy).

Toxicity: In Group A, grade 3/4 toxicities included: neutropenia, leukopenia, asthenia, alopecia, diarrhea, and headache. One patient died of progressive metastatic disease for whom the authors could not rule out trastuzumab-related cardiotoxicity.

Results: For Group A, the median overall survival was 31.2 months.

The authors concluded that the combination therapy (trastuzumab and docetaxel) had a greater therapeutic benefit for patients with metastatic breast cancer than docetaxel-only treatment.

Support: Several authors disclosed being consultants, advisors, or honoraria recipients from F. Hoffman-La Roche Pharmaceuticals and Aventis Pharmaceuticals. Roche manufactures and markets trastuzumab, and Aventis manufactures and markets docetaxel.

Correspondence: Michel Marty, M.D., Ph.D.

E-mail to a Friend Email Physician More Information